This is a summary of the European public assessment report (EPAR) for Firazyr. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Firazyr. For practical information about using Firazyr, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Therapeutic Area (MeSH)
ATC Code
B06AC02
ATC Item
icatibant
Pharmacotherapeutic Group
Cardiac therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| icatibant | N/A | 艾替班特 |
EMA Name
Firazyr
Medicine Name
Firazyr
Aliases
N/A
